CJEU Confirms 'Pay For Delay' Settlements Can Break EU Law
Ruling Will Help Competition Bodies Tackle 'Harmful Behaviour'
The UK’s Competition and Markets Authority has welcomed an EU Court of Justice ruling that settling patent disputes can break EU law by restricting competition. The case involved so-called "pay for delay" settlements regarding generic competitors to GlaxoSmithKline's antidepressant Seroxat (paroxetine).
You may also be interested in...
Patent-litigation settlements reached almost 20 years ago in the UK over GSK’s Seroxat paroxetine antidepressant may contravene EU competition law, an advocate general has advised the CJEU.
As Celltrion Healthcare prepares to roll out Remsima SC, its subcutaneous infliximab, in Europe – starting in the UK and Germany – Celltrion Healthcare’s UK commercial head, Matthew Eddleston, speaks to Generics Bulletin about how the innovative biosimilar will be positioned in the market.
Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.